Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ryan J Sullivan

Showing results (51-60 of 326) with videos related to

Pageof 33
Sort By:
Immunological Reviews|August 14, 2023
Effects of immune-related adverse events (irAEs) and their treatment on antitumor immune responsesSteven M Blum, Sherin J Rouhani, Ryan J Sullivan
Methods in Molecular Biology (Clifton, N.J.)|November 22, 2013
Assaying for BRAF V600E in tissue and blood in melanomaDavid J Panka, James W Mier, Ryan J Sullivan
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 30, 2016
Molecular Pathways: Receptor Ectodomain Shedding in Treatment, Resistance, and Monitoring of CancerMiles A Miller, Ryan J Sullivan, Douglas A Lauffenburger
Cancer|February 28, 2017
Immune checkpoint inhibitors in challenging populationsDouglas B Johnson, Ryan J Sullivan, Alexander M Menzies
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 4, 2013
The intersection of immune-directed and molecularly targeted therapy in advanced melanoma: where we have been, are, and will beRyan J Sullivan, Patricia M Lorusso, Keith T Flaherty
The Oncologist|July 9, 2016
Cardiogenic Shock and Respiratory Failure in a Patient With Metastatic Melanoma Receiving Trametinib TherapyDiane Tseng, Xenos L Mason, Tomas G Neilan, et al.
Organic Letters|October 5, 2016
Inherent vs Apparent Chemoselectivity in the Kumada-Corriu Cross-Coupling ReactionXiYe Hua, Jeanne Masson-Makdissi, Ryan J Sullivan, et al.
Frontiers in Pharmacology|May 23, 2022
Editorial: Toxicity Mechanism and Clinical Features of PD-1/PD-L1 Inhibitors in Treatment of Cancer, Volume IXiangyi Kong, Ryan J Sullivan, Caisheng Wu, et al.
Pediatric Blood & Cancer|February 11, 2020
Secondary histiocytic sarcoma with BRAF<sup>V600E</sup> mutation after T-cell acute lymphoblastic leukemia in a very young child with dramatic response to dabrafenib and trametinibVinayak Venkataraman, Lucas R Massoth, Ryan J Sullivan, et al.
Pediatric Blood & Cancer|June 1, 2021
Secondary histiocytic sarcoma with BRAF<sup>V600E</sup> mutation responsive to MAPK-targeted therapy presenting with recurrence with mTOR mutation responsive to mTOR-targeted therapyVinayak Venkataraman, Lucas R Massoth, Ryan J Sullivan, et al.
Pageof 33

Showing results (51-60 of 326) with videos related to

Sort By:
Pageof 33
Immunological Reviews|August 14, 2023
Effects of immune-related adverse events (irAEs) and their treatment on antitumor immune responsesSteven M Blum, Sherin J Rouhani, Ryan J Sullivan
Methods in Molecular Biology (Clifton, N.J.)|November 22, 2013
Assaying for BRAF V600E in tissue and blood in melanomaDavid J Panka, James W Mier, Ryan J Sullivan
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 30, 2016
Molecular Pathways: Receptor Ectodomain Shedding in Treatment, Resistance, and Monitoring of CancerMiles A Miller, Ryan J Sullivan, Douglas A Lauffenburger
Cancer|February 28, 2017
Immune checkpoint inhibitors in challenging populationsDouglas B Johnson, Ryan J Sullivan, Alexander M Menzies
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 4, 2013
The intersection of immune-directed and molecularly targeted therapy in advanced melanoma: where we have been, are, and will beRyan J Sullivan, Patricia M Lorusso, Keith T Flaherty
The Oncologist|July 9, 2016
Cardiogenic Shock and Respiratory Failure in a Patient With Metastatic Melanoma Receiving Trametinib TherapyDiane Tseng, Xenos L Mason, Tomas G Neilan, et al.
Organic Letters|October 5, 2016
Inherent vs Apparent Chemoselectivity in the Kumada-Corriu Cross-Coupling ReactionXiYe Hua, Jeanne Masson-Makdissi, Ryan J Sullivan, et al.
Frontiers in Pharmacology|May 23, 2022
Editorial: Toxicity Mechanism and Clinical Features of PD-1/PD-L1 Inhibitors in Treatment of Cancer, Volume IXiangyi Kong, Ryan J Sullivan, Caisheng Wu, et al.
Pediatric Blood & Cancer|February 11, 2020
Secondary histiocytic sarcoma with BRAF<sup>V600E</sup> mutation after T-cell acute lymphoblastic leukemia in a very young child with dramatic response to dabrafenib and trametinibVinayak Venkataraman, Lucas R Massoth, Ryan J Sullivan, et al.
Pediatric Blood & Cancer|June 1, 2021
Secondary histiocytic sarcoma with BRAF<sup>V600E</sup> mutation responsive to MAPK-targeted therapy presenting with recurrence with mTOR mutation responsive to mTOR-targeted therapyVinayak Venkataraman, Lucas R Massoth, Ryan J Sullivan, et al.
Pageof 33